2. Immunology/Inflammation
  3. CD6
  4. Itolizumab

Itolizumab  (Synonyms: Anti-Human CD6 Recombinant Antibody)

Cat. No.: HY-P99252 Purity: ≥99.0%
Data Sheet
SDS
COA
Technical Support

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.

For research use only. We do not sell to patients.

CAS No. : 1116433-11-4

Size Price Stock Quantity
1 mg USD 300 In-stock
5 mg USD 900 In-stock
10 mg USD 1440 In-stock
50 mg   Get quote  
100 mg   Get quote  

Get it by April 17 for select sizes. Order within 19 hrs 22 mins.

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Itolizumab Featured Recommendations:

Itolizumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19[1][2][3].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Humanized
IC50 & Target

CD6[1]
In Vitro

Itolizumab (100 μg/mL) inhibits T cell proliferation[4].
Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances acquisition of Th1 phenotype in PBMCs[4].
Itolizumab (40 μg/mL) reduces CD26hiCD161+?CD8+?T cells during culture of PBMCs overnight[5].
Itolizumab (40 μg/mL, 3-12 days) reduces the expression of IL-17 and IFN-γ in PBMCs stimulated in Th17 polarizing conditions[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Itolizumab Related Antibodies
In Vivo

Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD)[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Humanized xenograft mice, generated by intravenous transfer human PBMCs into 6-8 weeks old NOD/SCID IL2rγ-null (NSG)[7]
Dosage: 60 μg or 300μg
Administration: Intraperitoneal injection (i.p.), prior to PBMC transplantation.
Result: Decreased mortality compared to the vehicle (100% vs. 10%).
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT04128579Equillium|Biocon Limited
Lupus Erythematosus|Lupus Nephritis
October 1, 2019Phase 1
NCT05263999Equillium|Biocon Limited
Graft Versus Host Disease|GVHD|Acute-graft-versus-host Disease|Acute GVHD|aGVHD
April 29, 2022Phase 3
NCT05978544Biotech Pharmaceutical Co., Ltd.
Acute Respiratory Distress Syndrome
December 31, 2023Phase 1
Molecular Weight

146660.00

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Itolizumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Itolizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

Itolizumab1116433-11-4Anti-Human CD6 Recombinant AntibodyCD6Cluster of Differentiation 6Psoriasisrheumatoid arthritisRACOVID-19monoclonal antibodyT cellNSG micePBMCsGVHDInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Itolizumab
Cat. No.:
HY-P99252
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.